All Blogs

Oct 30, 2026

Summary Osteosarcoma treatment remains chemotherapy-dominated, with standard care combining surgery, chemotherapy, and, in selected cases, radiation therapy. The market continues to face significant unmet medical needs, with few treatments specifically approved for osteosarcoma. KHAPZORY is FDA-approved in t...

Oct 29, 2026

FDA Grants Breakthrough Device Designation to Pharaoh Neuro's Neurapheresis™ CSF Management System (Regulatory Update) On 28 October 2026, Pharaoh Neuro received FDA Breakthrough Device Designation for its Neurapheresis Cerebrospinal Fluid Management System, which was developed to accelerate the removal of blo...

Oct 28, 2026

Picture a woman reaching for a coffee cup with a hand that sits at the end of a prosthetic arm. She doesn’t look at it or think about it. Her hand just closes. A few years ago, that scene belonged mostly to science fiction. Today it is a clinical reality for a growing number of people, and the technology behind it ...

Oct 27, 2026

Roche’s Divarasib Sets a New Efficacy Benchmark in Previously Treated KRAS G12C-mutated Lung Cancer Roche reported pivotal findings from the Phase III KRASCENDO 1 trial, demonstrating that investigational divarasib, a next-generation KRAS G12C inhibitor, delivered superior efficacy compared with currently availa...

Oct 26, 2026

Summary GLP-1 therapies are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform, with expanding applications across cardiovascular disease, chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea (OSA). ...

Oct 23, 2026

Summary Vascular dementia is the second most common form of dementia after Alzheimer’s disease; however, no drug has been specifically approved for its treatment.  In 2025, the total number of diagnosed prevalent cases of vascular dementia across the seven major markets was estimated at 3 million, with ...

Oct 22, 2026

ProBio Completed NMPA Pre-Approval Inspection at Its Biologics Manufacturing Facility in China  On 21 October 2026, ProBio Inc. announced the successful completion of a pre-approval inspection conducted by China’s National Medical Products Administration (NMPA) at its biologics manufacturing facility in Nan...

Oct 20, 2026

Nouscom Secures Major Series D Funding and Prepares to Share Long-Term Clinical Findings in Lynch Syndrome Carriers at ESMO Nouscom has announced the completion of an oversubscribed €120 million ($135 million) Series D financing round. The investment was co-led by M Ventures and Revelation Partners, with partici...

Oct 21, 2026

Two people sit down to the same bowl of oatmeal. One feels steady and energized for hours. The other crashes by mid-morning, hungry and foggy. For decades, nutrition science treated both as the same "average eater" and handed them the same advice: eat more whole grains, cut saturated fat, watch your sugar. Yet anyo...

Oct 19, 2026

Summary Osteosarcoma is a rare, aggressive primary bone cancer that primarily affects adolescents and young adults. The total incident population across the seven major markets reached approximately 2,200 cases in 2025.  In the United States, Acrotech Biopharma’s Levoleucovorin (KHAPZORY) has received FDA ap...